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Aim: We aimed to study biological properties of human endometrial stromal cells in vitro. Materials and Methods: The endometrium 
samples (n = 5) were obtained by biopsy at the first phase of the menstrual cycle from women with endometrial hypoplasia. In all cases, 
a voluntary written informed consent was obtained from the patients. Endometrial fragments were dissociated by enzymatic treatment. 
The cells were cultured in DMEM/F12 supplemented with 10% FBS, 2 mМ L-glutamine and 1 ng/ml FGF-2 in a multi-gas incubator 
at 5% CO2 and 5% O2. At P3 the cells were subjected to immunophenotyping, multilineage differentiation, karyotype stability and colony 
forming efficiency. The cell secretome was assessed by BioRad Multiplex immunoassay kit. Results: Primary population of endometrial 
cells was heterogeneous and contained cells with fibroblast-like and epithelial-like morphology, but at P3 the majority of cell population 
had fibroblast-like morphology. The cells possessed typical for MSCs phenotype CD90+CD105+CD73+CD34-CD45-HLA-DR-. The 
cells also expressed CD140a, CD140b, CD146, and CD166 antigents; and were negative for CD106, CD184, CD271, and CD325. 
Cell doubling time was 29.6 ± 1.3 h. The cells were capable of directed osteogenic, adipogenic and chondrogenic differentiation. The 
cells showed 35.7% colony forming efficiency and a tendency to 3D spheroid formation. The GTG-banding assay confirmed the sta-
bility of eMSC karyotype during long-term culturing (up to P8). After 48 h incubation period in serum-free medium eMSC secreted 
anti-inflammatory IL-1ra, as well as IL-6, IL-8 and IFNγ, angiogenic factors VEGF, GM-CSF and FGF-2, chemokines IP-10 and 
MCP-1. Conclusion: Thus, cultured endometrial stromal cells meet minimal ISCT criteria for MSC. Proliferative potential, karyotype 
stability, multilineage plasticity and secretome profile make eMSC an attractive object for the regenerative medicine use.
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The development of cell biology and regenerative 
medicine methods open up new opportunities for the 
treatment of a number of pathological conditions, the 
study of their pathogenesis and the possibilities for 
correction.
Mesenchymal stem/stromal cells (MSC), the ma-
jor cell type for cell therapy, have been used in the 
clinic for approximately 15 years [1]. They are free 
of ethical concerns and have numerous sources, 
low immunogenicity and no risk of teratoma forma-
tion. For this reasons the MSC are the most com-
monly used stem cells in current clinical applications. 
Although MSC for cell therapy have been shown 
to be safe and effective, there are still challenges 
that need to be tackled before their wide application 
in the clinic.
MSC exist in almost all tissues. They can be easily 
isolated from the bone marrow, adipose tissue, umbili-
cal cord, dental pulp, and extra-embryonic tissues and 
can be successfully expanded in vitro [2–7].
The endometrium is a unique structure that is able 
to complete self-renewal over the month cycle, and 
undergoes these changes over 400 times during 
woman reproductive age [8]. A significant regenera-
tive potential is due to the presence of stem cells in the 
endometrium, such as mesenchymal, epithelial and 
endothelial progenitor cells [9]. The endometrium 
is a hormone-sensitive structure. For this reason, 
it is necessary to use tissue-specific MSC for develop-
ment of cell-based regenerative medicine approaches.
Interest for MSC using in regenerative medicine 
related not only of their structural integration in dam-
aged or diseased tissues and organs, but also for 
their trophic effect. So, the study of secretion profile 
of interleukins (IL), chemokines and growth factors 
of endometrial mesenchymal stromal cells (eMSC) 
is important task.
Considering of above mention the endometrium 
is a promising object for MSC isolation and in vitro 
large-scale expansion for their further application 
in reproductology and regenerative medicine.
MATERIALS AND METHODS
Experiments were done in accordance with the 
bioethics and biological safety norms confirmed 
by the Medical Company ilaya® Bioethics Commission 
permission.
The endometrium samples (n = 5) were obtained 
by biopsy at the first phase of the menstrual cycle 
from women with endometrial hypoplasia. In all cases, 
a voluntary written informed consent was obtained 
from the patients.
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Abbreviations used: eMSC — endometrial mesenchymal stromal 
cells; FACS — fluorescence-activated cell sorting; FGF-2 — basic 
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Cell isolation and culturing. Endometrial frag-
ments were dissociated by enzymatic treatment for 
1h in 0.1% collagenase IA and 0.1% pronase and 2% 
FBS. The cells were cultured in DMEM/F12 supplement-
ed with 10% FBS, 2 mМ L-glutamine and 1 ng/ml basic 
fibroblast growth factor (FGF-2) in a multi-gas incubator 
at 5% CO2 and 5% O2. All reagents were from Sigma-
Aldrich, USA. The P3 cells were used for the phenotype 
determination, directed adipogenic, osteogenic and 
chondrogenic differentiation assays, colony forming 
units test and karyotype stability.
Flow cytometry. The cell phenotype was assessed 
by fluorescence-activated cell sorting (FACS) on the 
BD FACSAria flow cytometer (BD Pharmingen, BD Ho-
rizon, USA). Staining with the monoclonal antibodies 
(PerCP-Cy5.5 mouse anti-human CD105, APC mouse 
anti-human CD73, FITC mouse anti-human CD90, PE-
Cy5 mouse anti-human HLA-DR, APC mouse anti-human 
CD34, FITC mouse anti-human CD45, PE-CF592 mouse 
anti-human CD146, BV421 mouse anti-human CD166, 
PE mouse anti-human CD106, PerCP-Cy5.5 mouse anti-
human CD140a, PE-CF592 mouse anti-human CD140b, 
APC mouse anti-human CD184, PE-CF592 mouse anti-
human CD271, FITC mouse anti-human CD325) was 
performed according to the manufacturer’s instructions 
(BD Pharmingen, BD Horizon, USA).
Fig. 1. Morphology of eMSC: 24 h in culture (a, b); 72 h in culture (c, d) ; cell culture at P3 (e, f). a, c — epiteloid-like morphology; 
b, d, e, f — fibroblast-like morphology. Phase-contrast microscopy. a, b, f — the bar = 50 μm; c, d, e — the bar = 100 μm
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The cell secretome was assessed by BioRad Multi-
plex immunoassay kit according to manufacturer’s in-
structions.
Directed multilineage differentiation. Adipo-
genic differentiation was performed in DMEM with high 
glucose content (4.5 g/l) (Sigma-Aldrich, USA) sup-
plemented with 5% horse serum (PAA, Austria), 10% 
FBS, 1 μM dexamethasone, 200 μM indomethacine, 
500 μM isobutylmethylxanthine and 5 μg/ml insulin (all 
from Sigma-Aldrich, USA). After 14 days the cells were 
fixed and stained with Oil Red O (Sigma-Aldrich, USA).
Osteogenic differentiation was performed in DMEM 
with low glucose content (1 g/l) with 10% FBS, 
100 nM dexamethasone, 10 mM β-glycerophosphate 
Fig. 2. Representative FACS graphics
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and 50 μg/ml ascorbate-2-phosphate (all from Sigma-
Aldrich, USA). After 21 days the cells were fixed and 
stained with Alizarin Red S (Sigma-Aldrich, USA).
Chondrogenic differentiation of cultures was carried 
out using the micromass culture method, 300,000 cells 
were centrifuged for 14 min at 2000 rpm to obtain 
a precipitate in 15-ml tubes (Nunc, USA). Further 
the cell pellets were cultured in chondrogenic induc-
tive medium containing DMEM with 4.5 g/l glucose 
(PAA, Germany) with addition of 50 μg/ml ascorbate-
2-phosphate (Sigma-Aldrich, USA), 40 μg/ml L-proline 
(Sigma-Aldrich, USA), 100 μg/ml sodium pyruvate (Sig-
ma-Aldrich, USA), 10 ng/ml rhTGF-β3 (Sigma, USA), 
10-7 M dexamethasone (Sigma-Aldrich, USA), 1% ITS 
containing 6.25 μg/ml insulin, 6.25 μg/ml transferrin, 
6.25 ng/ml selenic acid (Gibco, USA), 1.25 mg/ml bo-
vine serum albumin (Sigma-Aldrich, USA).
Colony forming units test. 100 cells were seeded 
per 100 mM cell culture dish and cultured for two 
weeks in standard culture medium with 20% FBS with-
out medium change. The colonies were fixed with cold 
96% ethanol and stained by Romanowsky.
GTG-banding was performed as decribed previ-
ously [10].
The population doubling time was calculated 
at http://www.doubling-time.com/compute.php [11].
RESULTS AND DISCUSSION
eMSC primary population morphology. We have 
obtained five eMSC cultures from five donors 34.0 ± 
3.3 years old. One of the characteristics of the MSC 
Fig. 4. Multilineage differentiation of eMSC. a — adipogenic differentiation. Red Oil O (red) and Romanowsky (violet) stain. Light 
microscopy. The bar = 50 μm; b — osteogenic differentiation. Alizarin Red S (red) stain. Light microscopy. The bar = 200 μm. c, d — 
chondrogenic differentiation. Light microscopy. The bar = 200 μm. c — Alcian Blue stain (blue), d — Goldner stain (black)
Fig. 3. eMSC 3D-spheroid formation. Phase-contrast microscopy. The bar = 200 μm (a); the bar = 10 μm (b); the bar = 50 μm (c)
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is their ability to adhere to plastic under standard cul-
ture conditions. After 24 h in culture the cells began 
to adhere to the plastic. The resulting cell population 
had a heterogeneous morphology (Fig. 1, a, b).
After 48 h of culture, part of the cells began to mi-
grate from non-dissociated conglomerates, forming 
colonies of small round cells with epithelial-like 
morphology. There were also single cells with typical 
fibroblast-like morphology. Further these cells with 
fibroblast-like morphology actively multiplied and 
formed colonies, whereas in epithelial-like colonies 
part of the cells died after 72 h in culture (Fig. 1, c, d).
At first two passages, population of eMSC re-
mained heterogeneous and consisted of fibroblast-
like and epithelial-like cells which is consistent with 
previous reports [8, 9].
However, at P3 the cell population became rather 
homogeneous: the majority of cells had fibroblast-like 
morphology, actively proliferated and formed a mono-
layer (Fig. 1, e, f).
eMSC immunophenotype. The results of the cell 
immunophenotyping at P3 are presented in Table 1 with 
representative histograms at Fig. 2. eMSC demonstrated 
high levels of MSC markers expression, e.g. CD73, CD90, 
CD105, CD90; and did not express markers of hemato-
poietic progenitor cells, e.g. CD34, CD45, HLA-DR. Posi-
tive expression of CD146+CD166+CD140a+CD140b+ was 
also studied. eMSC did not express CD106, CD184, 
CD271, CD325.
Table 1. Flow cytometry results of eMSC surface antigen expression (data 
presented as a percentage of parent population from 5 donors)
Antigens № 1 № 2 № 3 № 4 № 5 Mean ± SD
CD105 93.2 93.7 95.3 95 95.4 94.5 ± 1.0
CD73 95.4 98.9 99.2 99.1 97.9 98.1 ± 1.6
CD90 84.0 95.9 94.7 93.1 93.3 92.2 ± 4.7
CD34 0.1 0.3 0.3 0.2 0.2 0.2 ± 0.1
CD45 0.2 0.3 0.3 0.1 0.3 0.2 ± 0.9
HLA-DR 0.7 0.3 0.5 0.8 0.3 0.5 ± 0.2
CD140a 67.5 66.8 61.2 67.0 86.7 69.8 ± 9.7
CD140b 96.9 92.7 94.8 92.9 97.1 94.9 ± 2.1
CD146 85.2 78.6 94.7 75.1 83.1 83.4 ± 7.5
CD166 87.9 77.1 88.6 82.1 79.3 83.0 ± 5.1
CD106 0.3 0.6 0.3 0.2 0.3 0.35 ± 0.2
CD184 0.9 1.5 1.7 1.8 2.1 1.6 ± 0.4
CD271 6.4 4.2 5.1 5.3 6.9 5.58 ± 1.1
CD325 0.1 0.2 0.1 0.15 0.2 0.14 ± 0.1
Colony forming units efficiency and 3D spher-
oid formation of eMSC. The colony-forming units 
assay was also performed at P3. All cultures showed 
35.7 ± 2.3% colony forming efficiency. Moreover, when 
seeded at high density and cultured for a long time 
without splitting, all eMSC cell cultures demonstrated 
a tendency to 3D spheroid formation (Fig. 3).
Directed mult i l ineage dif ferentiat ion 
of eMSC. In accordance with the minimal criteria of the 
International Society for Cellular Therapy (ISCT) [12], 
multipotency is a mandatory property of any MSC and 
is determined by their ability for directed in vitro differen-
tiation into mesenchymal derived cell types (adipocytes, 
osteoblasts and chondrocytes).
All eMSC cultures successfully underwent adipo-
genic differentiation (Fig. 4, a). However, it was non-
canonic (comparing to bone marrow MSC where fat 
vacuoles are significantly larger and evenly distributed 
throughout the cytoplasm of the cell) as there were plen-
ty tiny lipid vacuoles located in the perinuclear region.
The eMSC cell culture also showed positive osteogenic 
differentiation with the production of Ca2+-mineralized 
extracellular matrix beginning from the day 14 of induction 
and with a high-density matrix at day 21 (Fig. 4, b).
The chondrogenic differentiation was also successful 
with a dense chondroid formation at day 21 of induction 
(Fig. 4, c, d).
eMSC secretome. After 48 h incubation period in se-
rum-free medium eMSC secreted anti-inflammatory IL-
1ra (74.6 ± 9.5 pg/ml), as well as IL-6 (29.8 ± 8.3 pg/ml), 
IL-8 (138.5 ± 33.3 pg/ml) and interferon gamma (IFNγ) 
(55.9 ± 3.8 pg/ml), angiogenic factors, vascular endo-
thelial growth factor (VEGF) (92.2 ± 19.8 pg/ml), granu-
locyte-macrophage colony-stimulating factor (GM-CSF) 
(133.2 ± 5.1 pg/ml) and FGF-2 (17.8 ± 4.3 pg/ml), che-
mokines interferon gamma-induced protein 10 (IP-10) 
(39.9 ± 3.3 pg/ml) and monocyte chemoattractant 
protein-1 (MCP-1) (41.1 ± 6.7 pg/ml) (Table 2).
Karyotype stability and cell doubling time 
of eMSC. Cell doubling time at P3 was in average 
29.6 ± 1.3 h for all five cell cultures. Moreover, eMSC 
maintained stable karyotype during long-term culturing 
up to P8 (Fig. 5). Altogether these data indicate a high 
proliferation rate and genetic stability of eMSC.
Fig. 5. Representative eMSC karyotype at P8: metaphase 
plate (a), karyogram (b). Normal female 46,XX karyotype 
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Table 2. Levels of cytokines and growth factors production of eMSC
Cytokines IL-1ra, pg/ml 74.6 ± 9.5
IL-6, pg/ml 29.8 ± 8.3
IL-8, pg/ml 138.5 ± 33.3
IFNγ, pg/ml 55.9 ± 3.8
Growth factors VEGF, pg/ml 92.2 ± 19.8
GM-CSF, pg/ml 133.2 ± 5.1
FGF-2, pg/ml 17.8 ± 4.3
Chemokines IP-10, pg/ml 39.9 ± 3.3
MCP-1, pg/ml 41.1 ± 6.7
Thus, obtained eMSC meet minimal ISCT criteria 
for MSCs, such as adherence to plastic in standard 
culture conditions, expression of typical phenotype 
markers and ability for the directed differentiation 
in vitro. eMSC are stable during long-term culturing. 
They also produce a range of cytokines, chemokines 
and growth factors. Proliferative potential, karyotype 
stability and secretome profile make them a perspec-
tive object for the use for the regenerative medicine 
application.
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